WO2007129329A3 - Extended release pharmaceutical formulation comprising venlafaxine hydrochloride - Google Patents

Extended release pharmaceutical formulation comprising venlafaxine hydrochloride Download PDF

Info

Publication number
WO2007129329A3
WO2007129329A3 PCT/IN2007/000177 IN2007000177W WO2007129329A3 WO 2007129329 A3 WO2007129329 A3 WO 2007129329A3 IN 2007000177 W IN2007000177 W IN 2007000177W WO 2007129329 A3 WO2007129329 A3 WO 2007129329A3
Authority
WO
WIPO (PCT)
Prior art keywords
extended release
pharmaceutical formulation
release pharmaceutical
venlafaxine
venlafaxine hydrochloride
Prior art date
Application number
PCT/IN2007/000177
Other languages
French (fr)
Other versions
WO2007129329A2 (en
Inventor
Nagesh Nagaraju
Manish Dhall
Satya Sankar Sahoo
Gour Mukherji
Original Assignee
Jubilant Organosys Ltd
Nagesh Nagaraju
Manish Dhall
Satya Sankar Sahoo
Gour Mukherji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jubilant Organosys Ltd, Nagesh Nagaraju, Manish Dhall, Satya Sankar Sahoo, Gour Mukherji filed Critical Jubilant Organosys Ltd
Publication of WO2007129329A2 publication Critical patent/WO2007129329A2/en
Publication of WO2007129329A3 publication Critical patent/WO2007129329A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Abstract

Disclosed herein an extended release pharmaceutical formulation of venlafaxine comprising venlafaxine or its pharmaceutical acceptable salts in the form of spheroids. Said spheroids having a core consisting of about 40 % to about 55 % by weight of venlafaxine hydrochloride, about 40 % to about 50 % by weight of microcrystalline cellulose, about 0.5 % to about 5% by weight of hydroxypropyl methylcellulose, wherein the core is coated employing a combination of water insoluble and water soluble polymers.
PCT/IN2007/000177 2006-05-08 2007-05-07 Extended release pharmaceutical formulation comprising venlafaxine hydrochloride WO2007129329A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1136DE2006 2006-05-08
IN1136/DEL/2006 2006-05-08

Publications (2)

Publication Number Publication Date
WO2007129329A2 WO2007129329A2 (en) 2007-11-15
WO2007129329A3 true WO2007129329A3 (en) 2008-03-13

Family

ID=38481229

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000177 WO2007129329A2 (en) 2006-05-08 2007-05-07 Extended release pharmaceutical formulation comprising venlafaxine hydrochloride

Country Status (1)

Country Link
WO (1) WO2007129329A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176486A1 (en) * 2006-11-14 2011-12-29 Sunstar Inc Oral composition containing crystalline cellulose surface-treated with water-soluble substance
US10561618B2 (en) * 2012-04-18 2020-02-18 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
IT201800003223A1 (en) 2018-03-02 2019-09-02 Milo Turri Pharmaceutical composition for use in the treatment of depressive and anxious syndromes

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999022724A2 (en) * 1997-11-05 1999-05-14 American Home Products Corporation Extended release formulation containing venlafaxin
US20020025339A1 (en) * 1996-03-25 2002-02-28 American Home Products Corporation Extended release formulation
WO2003041692A1 (en) * 2001-11-13 2003-05-22 Karma Pharm Ltd. Extended release compositions comprising as active compound venlafaxine hydrochloride
WO2003055475A1 (en) * 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
US20030190354A1 (en) * 2002-04-09 2003-10-09 Yoram Sela Extended release composition comprising as active compound venlafaxine hydrochloride
WO2003082261A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Extended release venlafaxine formulations
EP1473030A1 (en) * 2003-05-02 2004-11-03 Dexcel Ltd. Extended release Venlafaxine tablet formulation
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
US20050169985A1 (en) * 2004-02-04 2005-08-04 Sampad Bhattacharya Extended release formulation of venlafaxine hydrochloride
US20050244498A1 (en) * 2001-09-14 2005-11-03 Biovail Laboratories, Inc. Modified-release compositions of at least one form of venlafaxine
WO2006015485A1 (en) * 2004-08-12 2006-02-16 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025339A1 (en) * 1996-03-25 2002-02-28 American Home Products Corporation Extended release formulation
WO1999022724A2 (en) * 1997-11-05 1999-05-14 American Home Products Corporation Extended release formulation containing venlafaxin
US20050244498A1 (en) * 2001-09-14 2005-11-03 Biovail Laboratories, Inc. Modified-release compositions of at least one form of venlafaxine
WO2003041692A1 (en) * 2001-11-13 2003-05-22 Karma Pharm Ltd. Extended release compositions comprising as active compound venlafaxine hydrochloride
WO2003055475A1 (en) * 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
WO2003082261A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Extended release venlafaxine formulations
US20030190354A1 (en) * 2002-04-09 2003-10-09 Yoram Sela Extended release composition comprising as active compound venlafaxine hydrochloride
EP1473030A1 (en) * 2003-05-02 2004-11-03 Dexcel Ltd. Extended release Venlafaxine tablet formulation
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
US20050169985A1 (en) * 2004-02-04 2005-08-04 Sampad Bhattacharya Extended release formulation of venlafaxine hydrochloride
WO2006015485A1 (en) * 2004-08-12 2006-02-16 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride

Also Published As

Publication number Publication date
WO2007129329A2 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
EP2210591A3 (en) Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
WO2008149440A1 (en) Medicinal film preparation with rapidly dissolving property and flexibility
HRP20070353T3 (en) Extended release coated minitablets of venlafaxine hydrochloride
WO2008011335A3 (en) Metal binding compounds, metal binding compositions, and their uses
MX360389B (en) Gastric resistant pharmaceutical or nutraceutical formulation comprising one or more salts of alginic acid.
WO2012085043A3 (en) Rapidly disintegrating, solid coated dosage form
WO2009034541A3 (en) Controlled release pharmaceutical dosage forms of trimetazidine
WO2005072745A3 (en) Aqueous solutions comprising prednisolone and a cyclodextrin derivative
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2009106824A3 (en) Pharmaceutical formulations with a taste masking coating
WO2009066315A3 (en) Sustained release compositions of trimetazidine and process for preparation thereof
RS53363B (en) Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
WO2009153461A3 (en) Method for the synthesis of 7, 8-dimethoxy-l, 3-dihydro-2h-3-benzazepin-2-one, and the application thereof to the synthesis of ivabradine and the addition salts thereof with a pharmaceutically acceptable acid
WO2009038112A1 (en) Solid preparation comprising npyy5 receptor antagonist
WO2007129329A3 (en) Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
WO2009090670A8 (en) Stabilized sustained release composition of bupropion hydrochloride and process for preparing the same
NZ599742A (en) Improved oral pharmaceutical solid dosage form
WO2007016128A3 (en) Magnesium salt proton pump inhibitor dosage forms
WO2010100657A3 (en) Oral controlled release dosage forms for water soluble drugs
WO2010046932A3 (en) Extended release pharmaceutical composition of minocycline and process thereof
SI1994926T1 (en) Valsartan formulations
WO2007110753A3 (en) Extended release dosage forms of metoprolol
WO2008023390A3 (en) Modified release pharmaceutical composition of bupropion hydrochloride
WO2009075324A1 (en) Loxoprofen-containing aqueous plaster
WO2012010944A3 (en) Multiple unit tablet composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07736603

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07736603

Country of ref document: EP

Kind code of ref document: A2